<DOC>
	<DOC>NCT00545324</DOC>
	<brief_summary>In adult patients with mild persistent asthma, singulair® 10 mg will be at least as effective as low dose Inhaled Corticosteroids (ICS) in improving asthma symptom control or satisfaction over a 6 week comparison period.</brief_summary>
	<brief_title>First Step With Singulair® Therapy (0476-323)</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Montelukast</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<criteria>First time diagnosis of mild asthma symptoms which requires an antiinflammatory controller medication Patients not controlled with short acting beta2 agonist (sab) therapy (requiring more than one treatment per week but less than 7 per week) Patients dissatisfied with low dose ics therapy, or patients reluctant to take ics therapy, or patients insufficiently controlled due to noncompliance with low dose ics therapy through out the preceding 6 weeks Patient's forced expiratory volume in one second (fev1) is &lt; 80% of predicted value Patient on combination therapy Patient on long acting beta2 agonists Patient on using moderate to high doses of ICS. (ICS &gt;250 &amp;micro g/day flovent&amp;reg; or equivalent per day)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>